JP2002528490A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528490A5 JP2002528490A5 JP2000579211A JP2000579211A JP2002528490A5 JP 2002528490 A5 JP2002528490 A5 JP 2002528490A5 JP 2000579211 A JP2000579211 A JP 2000579211A JP 2000579211 A JP2000579211 A JP 2000579211A JP 2002528490 A5 JP2002528490 A5 JP 2002528490A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- defined above
- phenyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 33
- 235000019256 formaldehyde Nutrition 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 26
- 229910052736 halogen Inorganic materials 0.000 description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 25
- 150000002367 halogens Chemical class 0.000 description 23
- 125000000217 alkyl group Chemical group 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 21
- 238000000034 method Methods 0.000 description 20
- 125000001072 heteroaryl group Chemical group 0.000 description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 208000006673 asthma Diseases 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 229910052794 bromium Inorganic materials 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 11
- 125000000623 heterocyclic group Chemical group 0.000 description 11
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 8
- 206010019663 Hepatic failure Diseases 0.000 description 8
- 229910052801 chlorine Inorganic materials 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 229910052740 iodine Inorganic materials 0.000 description 8
- 231100000835 liver failure Toxicity 0.000 description 8
- 208000007903 liver failure Diseases 0.000 description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 239000011630 iodine Substances 0.000 description 7
- 206010029240 Neuritis Diseases 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000003779 hair growth Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 125000001624 naphthyl group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 201000004384 Alopecia Diseases 0.000 description 4
- 208000009137 Behcet syndrome Diseases 0.000 description 4
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 4
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010036105 Polyneuropathy Diseases 0.000 description 4
- 206010046851 Uveitis Diseases 0.000 description 4
- 206010047642 Vitiligo Diseases 0.000 description 4
- 231100000360 alopecia Toxicity 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 125000005605 benzo group Chemical group 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960003444 immunosuppressant agent Drugs 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 208000023589 ischemic disease Diseases 0.000 description 4
- 206010023332 keratitis Diseases 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 208000019629 polyneuritis Diseases 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- -1 pyrrolidyl Chemical group 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
- XGWIJUOSCAQSSV-XHDPSFHLSA-N (S,S)-hexythiazox Chemical compound S([C@H]([C@@H]1C)C=2C=CC(Cl)=CC=2)C(=O)N1C(=O)NC1CCCCC1 XGWIJUOSCAQSSV-XHDPSFHLSA-N 0.000 description 2
- 125000006091 1,3-dioxolane group Chemical group 0.000 description 2
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 2
- 201000010000 Agranulocytosis Diseases 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000028185 Angioedema Diseases 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 208000032467 Aplastic anaemia Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 2
- 206010015218 Erythema multiforme Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010018691 Granuloma Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 208000005100 Herpetic Keratitis Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 201000002287 Keratoconus Diseases 0.000 description 2
- GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 description 2
- 208000012309 Linear IgA disease Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 208000027530 Meniere disease Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 208000012896 Peritoneal disease Diseases 0.000 description 2
- 208000031845 Pernicious anaemia Diseases 0.000 description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
- 206010036774 Proctitis Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 208000003670 Pure Red-Cell Aplasia Diseases 0.000 description 2
- 208000006311 Pyoderma Diseases 0.000 description 2
- 206010037779 Radiculopathy Diseases 0.000 description 2
- 208000033626 Renal failure acute Diseases 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010038910 Retinitis Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010048908 Seasonal allergy Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 2
- 208000012339 Vascular injury Diseases 0.000 description 2
- 206010047115 Vasculitis Diseases 0.000 description 2
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 208000008445 altitude sickness Diseases 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical group C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 201000010002 cicatricial pemphigoid Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 201000010884 herpes simplex virus keratitis Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000003463 hyperproliferative effect Effects 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 201000002597 ichthyosis vulgaris Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 201000010659 intrinsic asthma Diseases 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 2
- 208000023569 ischemic bowel disease Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 2
- 201000011486 lichen planus Diseases 0.000 description 2
- 231100000149 liver necrosis Toxicity 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 208000008585 mastocytosis Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000012753 partial hepatectomy Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 201000004338 pollen allergy Diseases 0.000 description 2
- 201000006292 polyarteritis nodosa Diseases 0.000 description 2
- 208000005987 polymyositis Diseases 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 125000001725 pyrenyl group Chemical group 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- ZBZJXHCVGLJWFG-UHFFFAOYSA-N trichloromethyl(.) Chemical compound Cl[C](Cl)Cl ZBZJXHCVGLJWFG-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 210000004885 white matter Anatomy 0.000 description 2
- WDXYVJKNSMILOQ-UHFFFAOYSA-N 1,3,2-dioxathiolane 2-oxide Chemical compound O=S1OCCO1 WDXYVJKNSMILOQ-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- SIJBDWPVNAYVGY-UHFFFAOYSA-N 2,2-dimethyl-1,3-dioxolane Chemical compound CC1(C)OCCO1 SIJBDWPVNAYVGY-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 206010061728 Bone lesion Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012441 Dermatitis bullous Diseases 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- ULFHKWHZALMVRA-UHFFFAOYSA-N [4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl] n-ethylcarbamate Chemical compound C1CC(OC(=O)NCC)CCC1(C=1C=CC=CC=1)CNC(=O)C1=CC=CC=C1OC ULFHKWHZALMVRA-UHFFFAOYSA-N 0.000 description 1
- AREGPDFKGNNJAE-UHFFFAOYSA-N [4-[[(2-methoxybenzoyl)amino]methyl]-4-phenylcyclohexyl] n-methylcarbamate Chemical compound C1CC(OC(=O)NC)CCC1(C=1C=CC=CC=1)CNC(=O)C1=CC=CC=C1OC AREGPDFKGNNJAE-UHFFFAOYSA-N 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 239000013078 crystal Chemical group 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000003903 intestinal lesions Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002935 megaloblast Anatomy 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003658 preventing hair loss Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10641698P | 1998-10-30 | 1998-10-30 | |
| US60/106,416 | 1998-10-30 | ||
| PCT/US1999/024949 WO2000025770A1 (en) | 1998-10-30 | 1999-10-26 | Carbocyclic potassium channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002528490A JP2002528490A (ja) | 2002-09-03 |
| JP2002528490A5 true JP2002528490A5 (cg-RX-API-DMAC10.html) | 2006-08-10 |
| JP4504570B2 JP4504570B2 (ja) | 2010-07-14 |
Family
ID=22311305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000579211A Expired - Fee Related JP4504570B2 (ja) | 1998-10-30 | 1999-10-26 | 炭素環式カリウムチャンネル阻害薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6632836B1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1143965B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4504570B2 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE423557T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU764477B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2348742C (cg-RX-API-DMAC10.html) |
| DE (1) | DE69940480D1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2000025770A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19923086A1 (de) * | 1999-05-20 | 2000-11-23 | Aventis Pharma Gmbh | Cinnamoylaminoalkyl-substituierte Benzolsulfonamidderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GB0012214D0 (en) * | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| EP1299362A4 (en) * | 2000-07-05 | 2004-11-03 | Synaptic Pharma Corp | SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE |
| AU2002240051B2 (en) * | 2001-01-30 | 2006-06-01 | Merck & Co., Inc. | Method for identifying maxi-K channel blockers |
| DE10153346A1 (de) * | 2001-10-29 | 2004-04-22 | Grünenthal GmbH | Substituierte Indole |
| US20040115739A1 (en) * | 2002-01-25 | 2004-06-17 | Garcia Maria L | Method for identifying maxi-k channel blockers for use in lowering elevated intraocular pressure using hek-293 cells |
| TW200307539A (en) * | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| SI1539157T1 (sl) * | 2002-09-18 | 2013-11-29 | Trustees Of The University Of Pennsylvania | Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije |
| AU2003286701B2 (en) * | 2002-10-30 | 2008-12-18 | Merck Sharp & Dohme Corp. | Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity |
| CA2521907A1 (en) * | 2003-04-10 | 2004-10-21 | Pfizer Inc. | Bicyclic compounds as nr2b receptor antagonists |
| JP2007505932A (ja) | 2003-09-18 | 2007-03-15 | マクサイト， インコーポレイテッド | 経強膜送達 |
| US7598412B2 (en) * | 2003-10-08 | 2009-10-06 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| NZ548212A (en) | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| EP1781635B1 (en) | 2004-07-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| US7569589B2 (en) | 2004-07-29 | 2009-08-04 | Merck & Co., Inc. | Potassium channel inhibitors |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| CA2597590A1 (en) | 2005-02-09 | 2006-08-17 | Macusight, Inc. | Formulations for ocular treatment |
| US7915410B2 (en) * | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
| US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| KR101294014B1 (ko) * | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| KR101478164B1 (ko) | 2006-02-09 | 2014-12-31 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| AU2007230964B2 (en) | 2006-03-23 | 2012-07-19 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| BRPI0709961A2 (pt) * | 2006-04-11 | 2011-08-02 | Novartis Ag | compostos orgánicos |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7801502B2 (en) * | 2006-12-18 | 2010-09-21 | Aai Corporation | Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems |
| EA200900821A1 (ru) * | 2006-12-22 | 2010-02-26 | Новартис Аг | Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv) |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| KR20120075500A (ko) * | 2008-03-27 | 2012-07-06 | 그뤼넨탈 게엠베하 | 치환된 4-아미노사이클로헥산 유도체 |
| AU2009228637B2 (en) * | 2008-03-27 | 2013-12-19 | Grunenthal Gmbh | (Hetero-)aryl cyclohexane derivatives |
| US8409628B2 (en) | 2010-02-04 | 2013-04-02 | Penguin IP Holdings, Inc. | Methods and compositions for oxygenation of skin to treat skin disorders |
| WO2011123619A2 (en) | 2010-03-31 | 2011-10-06 | Penguin Ip Holdings Inc. | Permeable mixtures, methods and compositions for the skin |
| WO2011153359A1 (en) | 2010-06-04 | 2011-12-08 | Albany Molecular Research, Inc. | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
| AU2012331256A1 (en) * | 2011-11-04 | 2014-05-22 | Syngenta Participations Ag | Pesticidal compounds |
| WO2013093508A2 (en) * | 2011-12-22 | 2013-06-27 | Oslo University Hospital Hf | Wnt pathway inhibitors |
| TWI598325B (zh) * | 2012-10-12 | 2017-09-11 | Ｈ 朗德貝克公司 | 苯甲醯胺類 |
| TW201427947A (zh) | 2012-10-12 | 2014-07-16 | Lundbeck & Co As H | 環狀胺 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| EA201790806A1 (ru) | 2014-11-05 | 2017-11-30 | Флексус Байосайенсиз, Инк. | Иммунорегулирующие средства |
| WO2016105448A1 (en) * | 2014-12-22 | 2016-06-30 | Darryl Rideout | Imidazoline receptor type 1 ligands for use as therapeutics |
| JP7478251B2 (ja) * | 2019-12-14 | 2024-05-02 | シャンハイ イースト ホスピタル（イースト ホスピタル，トンジ ユニバーシティ スクール オブ メディシン） | イオンチャネルアンタゴニスト／遮断剤およびその用途 |
| CN111812243B (zh) * | 2020-07-21 | 2022-06-03 | 中南大学湘雅二医院 | 一种消减全血环孢素测定的基质效应的分析方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL84944A (en) * | 1987-01-19 | 1992-02-16 | Ici Plc | Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation |
| GB8707123D0 (en) | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
| IL88314A (en) | 1987-11-18 | 1994-05-30 | Tanabe Seiyaku Co | Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them |
| FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
| US5179216A (en) * | 1990-08-16 | 1993-01-12 | American Home Products Corporation | N,n', n'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-coa:cholesterol-acyl transferase |
| ATE167473T1 (de) | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
| ZA96211B (en) | 1995-01-12 | 1996-07-26 | Teva Pharma | Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| JP2000510833A (ja) * | 1996-05-06 | 2000-08-22 | イーライ・リリー・アンド・カンパニー | 抗―ウイルス性化合物群 |
| US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
| TW467902B (en) | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| US6194458B1 (en) * | 1998-10-30 | 2001-02-27 | Merck & Co., Inc. | Benzamide potassium channel inhibitors |
-
1999
- 1999-10-21 US US09/422,143 patent/US6632836B1/en not_active Expired - Fee Related
- 1999-10-26 WO PCT/US1999/024949 patent/WO2000025770A1/en not_active Ceased
- 1999-10-26 CA CA002348742A patent/CA2348742C/en not_active Expired - Fee Related
- 1999-10-26 DE DE69940480T patent/DE69940480D1/de not_active Expired - Lifetime
- 1999-10-26 AU AU11331/00A patent/AU764477B2/en not_active Ceased
- 1999-10-26 AT AT99955159T patent/ATE423557T1/de not_active IP Right Cessation
- 1999-10-26 EP EP99955159A patent/EP1143965B1/en not_active Expired - Lifetime
- 1999-10-26 JP JP2000579211A patent/JP4504570B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002528493A5 (cg-RX-API-DMAC10.html) | ||
| JP2007515432A5 (cg-RX-API-DMAC10.html) | ||
| JP2010540593A5 (cg-RX-API-DMAC10.html) | ||
| EP1948176B1 (en) | Diaryl ureas for treating pulmonary hypertension | |
| JP2006528980A5 (cg-RX-API-DMAC10.html) | ||
| CA2472713A1 (en) | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists | |
| JP2018536693A (ja) | 睡眠関連呼吸障害を治療するためのＴＡＳＫ−１およびＴＡＳＫ−２チャネルの遮断薬としての２−フェニル−３−（ピペラジノメチル）イミダゾ［１，２−ａ］ピリジン誘導体 | |
| JP2016500111A5 (cg-RX-API-DMAC10.html) | ||
| JP2005526857A5 (cg-RX-API-DMAC10.html) | ||
| WO2018181883A1 (ja) | ４－ピリドン化合物またはその塩、それを含む医薬組成物および剤 | |
| TW201010990A (en) | New combination-408 | |
| JP2021519764A5 (cg-RX-API-DMAC10.html) | ||
| JP5084736B2 (ja) | 肺高血圧を処置するためのジアリールウレア | |
| JP2009537535A (ja) | エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物 | |
| US10220072B2 (en) | Mesalamine for the treatment of cancer | |
| JP2000516257A (ja) | タキキニンアンタゴニスト | |
| JP2014509297A5 (cg-RX-API-DMAC10.html) | ||
| JP2021107447A5 (cg-RX-API-DMAC10.html) | ||
| JP2001523644A5 (cg-RX-API-DMAC10.html) | ||
| EP2305234A1 (en) | Pharmaceutical composition for treatment or prevention of hbv infection | |
| US10857113B2 (en) | Bezafibrate for the treatment of cancer | |
| JP6958797B2 (ja) | Ｃ型肝炎ウイルス阻害剤およびその使用 | |
| JP4688681B2 (ja) | 好中球増多抑制剤 | |
| EP1922070A1 (en) | A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma | |
| ES2356931T3 (es) | Diaril ureas para tratar la hipertensión pulmonar. |